Chengdu Olymvax Biopharmaceuticals (688319.SS) Earnings Analysis
Chengdu Olymvax Biopharmaceuticals (688319.SS) next reports earnings on 2026-08-14. Trailing P/E 193.48.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 688319.SS next report earnings?
| Next earnings date | 2026-08-14 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
688319.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-27 | -0.0621 CNY | n/a | n/a | n/a |
| 2025-10-30 | 0.08456 CNY | n/a | n/a | n/a |
| 2025-04-25 | -0.0174 CNY | n/a | n/a | n/a |
| 2024-08-21 | -0.00481 CNY | n/a | n/a | n/a |
688319.SS valuation and analyst view
| Trailing P/E | 193.48 |
|---|---|
| Trailing EPS | 0.13935 CNY |
| Price / book | 11.76 |
| Dividend yield | 0.00% |
| Market cap | 10.91B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Chengdu Olymvax Biopharmaceuticals (688319.SS)'s next earnings date?
Chengdu Olymvax Biopharmaceuticals is next scheduled to report on 2026-08-14.
Did 688319.SS beat earnings last quarter?
Consensus estimate data was not available for 688319.SS's 2026-02-27 report.
What is 688319.SS's current P/E ratio and EPS?
688319.SS trades at a trailing P/E of 193.48 on trailing EPS of 0.13935291568299 CNY.
What do analysts rate 688319.SS?
688319.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.